Literature DB >> 31289032

Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms.

Emery H Bresnick1,2,3,4, Kirby D Johnson1,2,3,4.   

Abstract

Intensive scrutiny of human genomes has unveiled considerable genetic variation in coding and noncoding regions. In cancers, including those of the hematopoietic system, genomic instability amplifies the complexity and functional consequences of variation. Although elucidating how variation impacts the protein-coding sequence is highly tractable, deciphering the functional consequences of variation in noncoding regions (genome reading), including potential transcriptional-regulatory sequences, remains challenging. A crux of this problem is the sheer abundance of gene-regulatory sequence motifs (cis elements) mediating protein-DNA interactions that are intermixed in the genome with thousands of look-alike sequences lacking the capacity to mediate functional interactions with proteins in vivo. Furthermore, transcriptional enhancers harbor clustered cis elements, and how altering a single cis element within a cluster impacts enhancer function is unpredictable. Strategies to discover functional enhancers have been innovated, and human genetics can provide vital clues to achieve this goal. Germline or acquired mutations in functionally critical (essential) enhancers, for example at the GATA2 locus encoding a master regulator of hematopoiesis, have been linked to human pathologies. Given the human interindividual genetic variation and complex genetic landscapes of hematologic malignancies, enhancer corruption, creation, and expropriation by new genes may not be exceedingly rare mechanisms underlying disease predisposition and etiology. Paradigms arising from dissecting essential enhancer mechanisms can guide genome-reading strategies to advance fundamental knowledge and precision medicine applications. In this review, we provide our perspective of general principles governing the function of blood disease-linked enhancers and GATA2-centric mechanisms.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31289032      PMCID: PMC6616255          DOI: 10.1182/bloodadvances.2019000378

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  137 in total

1.  GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.

Authors:  Philipp A Greif; Annika Dufour; Nikola P Konstandin; Bianka Ksienzyk; Evelyn Zellmeier; Belay Tizazu; Jutta Sturm; Tobias Benthaus; Tobias Herold; Marjan Yaghmaie; Petra Dörge; Karl-Peter Hopfner; Andreas Hauser; Alexander Graf; Stefan Krebs; Helmut Blum; Purvi M Kakadia; Stephanie Schneider; Eva Hoster; Friederike Schneider; Martin Stanulla; Jan Braess; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard J Woermann; Wolfgang Hiddemann; Karsten Spiekermann; Stefan K Bohlander
Journal:  Blood       Date:  2012-05-30       Impact factor: 22.113

2.  Proximity among distant regulatory elements at the beta-globin locus requires GATA-1 and FOG-1.

Authors:  Christopher R Vakoc; Danielle L Letting; Nele Gheldof; Tomoyuki Sawado; M A Bender; Mark Groudine; Mitchell J Weiss; Job Dekker; Gerd A Blobel
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

Review 3.  Functional and mechanistic diversity of distal transcription enhancers.

Authors:  Michael Bulger; Mark Groudine
Journal:  Cell       Date:  2011-02-04       Impact factor: 41.582

Review 4.  How best to identify chromosomal interactions: a comparison of approaches.

Authors:  James O J Davies; A Marieke Oudelaar; Douglas R Higgs; Jim R Hughes
Journal:  Nat Methods       Date:  2017-01-31       Impact factor: 28.547

5.  Knockout mice created by TALEN-mediated gene targeting.

Authors:  Young Hoon Sung; In-Jeoung Baek; Duk Hyoung Kim; Jisun Jeon; Jaehoon Lee; Kyunghee Lee; Daewon Jeong; Jin-Soo Kim; Han-Woong Lee
Journal:  Nat Biotechnol       Date:  2013-01       Impact factor: 54.908

6.  Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences.

Authors:  J Banerji; S Rusconi; W Schaffner
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

7.  Targeted deletion of 5'HS2 of the murine beta-globin LCR reveals that it is not essential for proper regulation of the beta-globin locus.

Authors:  S Fiering; E Epner; K Robinson; Y Zhuang; A Telling; M Hu; D I Martin; T Enver; T J Ley; M Groudine
Journal:  Genes Dev       Date:  1995-09-15       Impact factor: 11.361

8.  Comprehensive mapping of long-range interactions reveals folding principles of the human genome.

Authors:  Erez Lieberman-Aiden; Nynke L van Berkum; Louise Williams; Maxim Imakaev; Tobias Ragoczy; Agnes Telling; Ido Amit; Bryan R Lajoie; Peter J Sabo; Michael O Dorschner; Richard Sandstrom; Bradley Bernstein; M A Bender; Mark Groudine; Andreas Gnirke; John Stamatoyannopoulos; Leonid A Mirny; Eric S Lander; Job Dekker
Journal:  Science       Date:  2009-10-09       Impact factor: 47.728

9.  Genome-wide prediction of cis-regulatory regions using supervised deep learning methods.

Authors:  Yifeng Li; Wenqiang Shi; Wyeth W Wasserman
Journal:  BMC Bioinformatics       Date:  2018-05-31       Impact factor: 3.169

10.  CRISPR RNA-guided activation of endogenous human genes.

Authors:  Morgan L Maeder; Samantha J Linder; Vincent M Cascio; Yanfang Fu; Quan H Ho; J Keith Joung
Journal:  Nat Methods       Date:  2013-07-25       Impact factor: 28.547

View more
  10 in total

1.  Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder.

Authors:  Minggao Liang; Asim Soomro; Subia Tasneem; Luis E Abatti; Azad Alizada; Xuefei Yuan; Liis Uusküla-Reimand; Lina Antounians; Sana Akhtar Alvi; Andrew D Paterson; Georges-Étienne Rivard; Ian C Scott; Jennifer A Mitchell; Catherine P M Hayward; Michael D Wilson
Journal:  Blood       Date:  2020-12-03       Impact factor: 22.113

Review 2.  Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

Authors:  Anna L Brown; Christopher N Hahn; Hamish S Scott
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

3.  Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer.

Authors:  Shifeng Yang; Xiaoming Zou; Hao Yang; Jiacheng Li; Ange Zhang; Lisha Zhang; Changjian Li; Lei Zhu; Zhen Ma
Journal:  Front Genet       Date:  2022-04-29       Impact factor: 4.772

4.  Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.

Authors:  Johannes Zuber; Ruud Delwel; Leonie Smeenk; Sophie Ottema; Roger Mulet-Lazaro; Anja Ebert; Marije Havermans; Andrea Arricibita Varea; Michaela Fellner; Dorien Pastoors; Stanley van Herk; Claudia Erpelinck-Verschueren; Tim Grob; Remco M Hoogenboezem; François G Kavelaars; Daniel R Matson; Emery H Bresnick; Eric M Bindels; Alex Kentsis
Journal:  Cancer Discov       Date:  2021-05-12       Impact factor: 39.397

5.  Conditionally pathogenic genetic variants of a hematopoietic disease-suppressing enhancer.

Authors:  Alexandra A Soukup; Daniel R Matson; Peng Liu; Kirby D Johnson; Emery H Bresnick
Journal:  Sci Adv       Date:  2021-12-10       Impact factor: 14.136

6.  Chromatin accessibility associates with protein-RNA correlation in human cancer.

Authors:  Akshay Sanghi; Joshua J Gruber; Ahmed Metwally; Lihua Jiang; Warren Reynolds; John Sunwoo; Lisa Orloff; Howard Y Chang; Maya Kasowski; Michael P Snyder
Journal:  Nat Commun       Date:  2021-09-30       Impact factor: 14.919

7.  A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer.

Authors:  Tianyu Cao; Yuanyuan Lu; Qi Wang; Hongqiang Qin; Hongwei Li; Hao Guo; Minghui Ge; Sarah E Glass; Bhuminder Singh; Wenyao Zhang; Jiaqiang Dong; Feng Du; Airong Qian; Ye Tian; Xin Wang; Cunxi Li; Kaichun Wu; Daiming Fan; Yongzhan Nie; Robert J Coffey; Xiaodi Zhao
Journal:  J Clin Invest       Date:  2022-03-15       Impact factor: 14.808

Review 8.  Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?

Authors:  Emery H Bresnick; Mabel M Jung; Koichi R Katsumura
Journal:  Blood Adv       Date:  2020-09-22

9.  The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.

Authors:  Ana Rio-Machin; Tom Vulliamy; Nele Hug; Amanda Walne; Kiran Tawana; Shirleny Cardoso; Alicia Ellison; Nikolas Pontikos; Jun Wang; Hemanth Tummala; Ahad Fahad H Al Seraihi; Jenna Alnajar; Findlay Bewicke-Copley; Hannah Armes; Michael Barnett; Adrian Bloor; Csaba Bödör; David Bowen; Pierre Fenaux; Andrew Green; Andrew Hallahan; Henrik Hjorth-Hansen; Upal Hossain; Sally Killick; Sarah Lawson; Mark Layton; Alison M Male; Judith Marsh; Priyanka Mehta; Rogier Mous; Josep F Nomdedéu; Carolyn Owen; Jiri Pavlu; Elspeth M Payne; Rachel E Protheroe; Claude Preudhomme; Nuria Pujol-Moix; Aline Renneville; Nigel Russell; Anand Saggar; Gabriela Sciuccati; David Taussig; Cynthia L Toze; Anne Uyttebroeck; Peter Vandenberghe; Brigitte Schlegelberger; Tim Ripperger; Doris Steinemann; John Wu; Joanne Mason; Paula Page; Susanna Akiki; Kim Reay; Jamie D Cavenagh; Vincent Plagnol; Javier F Caceres; Jude Fitzgibbon; Inderjeet Dokal
Journal:  Nat Commun       Date:  2020-02-25       Impact factor: 14.919

10.  GATA2 deficiency syndrome: A decade of discovery.

Authors:  Claire C Homan; Parvathy Venugopal; Peer Arts; Nur H Shahrin; Simone Feurstein; Lesley Rawlings; David M Lawrence; James Andrews; Sarah L King-Smith; Natasha L Harvey; Anna L Brown; Hamish S Scott; Christopher N Hahn
Journal:  Hum Mutat       Date:  2021-08-31       Impact factor: 4.700

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.